Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Pyronaridine and Piperaquine in Healthy Volunteers
NCT05160363Phase 1Completed
- Sponsor
- Medicines for Malaria Venture
- Start
- Feb 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pyronaridine and piperaquine in malaria (4 arms), sponsored by Medicines for Malaria Venture. Primary endpoint: Treatment-Emergent Adverse Events. Started Feb 2022; status: completed.
02
Drugs
pyronaridinepiperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05160363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05160363.